Pressure BioSciences (OTCQB: PBIO) (“PBI”), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables and platform technology solutions to the worldwide biotechnology and other industries, today announced the successful application of its Ultra Shear Technology(TM) (“UST(TM)”) platform. According to the update, the novel UST platform was used for the development of more potent formulations of wide-ranging nutraceuticals of high therapeutic value, allowing for more controlled dosing and opportunities for lower cost solutions for both manufacturers and consumers. Specifically, PBI reported breakthrough results in processing one of the most powerful antioxidants known to science, astaxanthin (“AsX”), in extremely fine and uniform, monodisperse nanoemulsions of oil in water. These results are critically important for fast and efficient absorption by the water-based biochemistry of humans and animals. “Nanoemulsions produced by PBI’s UST platform encapsulate AsX in extremely small oil droplets ranging in size from 30-60 nm in diameter*,” said Gary B. Smejkal, senior research scientist at PBI, explaining the breakthrough achieved by the company. “Because these particles are so small, they do not scatter light and thus appear as clear ruby red liquids that disperse freely in water or other clear beverages. The enhanced oral bioavailability of AsX corresponding to droplet size reduction is well-established and has been published**.”
To view the full press release, visit
https://ibn.fm/ffrin
About Pressure BioSciences Inc.
Pressure BioSciences is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. The company’s products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions safely and reproducibly (e.g., cell lysis, biomolecule extraction). The company’s primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil and plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of its pressure-based technologies in the following areas: (1) recently acquired, patented technology from BaroFold Inc. (the BaroFold technology) to allow entry into the bio-pharma contract services sector, and (2) recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies. For more information about the company, visit
www.PressureBioSciences.com.
*https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8150732/
**https://www.academia.edu/12327321/Enhanced_Oral_Bioavailability_of_Astaxanthin_with_Droplet_Size_Reduction
NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at
http://ibn.fm/PBIO
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.